Magnetic resonance imaging fails to show evidence of reduced endolymphatic hydrops in gentamicin treatment of Ménière's disease

To verify the hypothesis that intratympanic (IT) gentamicin (Gent) treatment in Ménière's disease (MD) is capable of reducing endolymphatic hydrops (EH), as evaluated by 3-dimensional fluid-attenuated inversion recovery (3D-FLAIR) sequence in a 3-Tesla magnetic resonance imaging (MRI) unit, aft...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Otology & neurotology Ročník 33; číslo 4; s. 629
Hlavní autori: Fiorino, Francesco, Pizzini, Francesca B, Barbieri, Franco, Beltramello, Alberto
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.06.2012
Predmet:
Adult
Aged
Ear, Inner - pathology
Endolymphatic Hydrops - etiology
Endolymphatic Hydrops - pathology
Female
Gentamicins - therapeutic use
Humans
Image Processing, Computer-Assisted
Imaging, Three-Dimensional
Magnetic Resonance Imaging
Male
Meniere Disease - complications
Meniere Disease - drug therapy
Middle Aged
ISSN:1537-4505, 1537-4505
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:To verify the hypothesis that intratympanic (IT) gentamicin (Gent) treatment in Ménière's disease (MD) is capable of reducing endolymphatic hydrops (EH), as evaluated by 3-dimensional fluid-attenuated inversion recovery (3D-FLAIR) sequence in a 3-Tesla magnetic resonance imaging (MRI) unit, after IT gadolinium administration. A total of 8 patients (5 men and 3 women; aged 40-78 yr; median, 60 yr) with definite MD participated in the investigation. The duration of the disease ranged from 1 to 10 years (median, 4 yr), with a prevalence of vertigo spells of 1 to 6 per month (median, 3.1), as calculated in the last 6 months. A 3D-FLAIR MRI was performed 24 hours after IT injection of diluted gadobutrol. Intratympanic Gent injection was performed in a period variable from 1 to 3 weeks after 3D-FLAIR MRI. A single-shot administration protocol was attempted with additional injections administered on demand in the case of relapsing vertigo spells. MRI was repeated after 3 to 12 months (median, 8 mo) after treatment. The degree and extension of EH as evaluated by 3D-FLAIR MRI was compared from images obtained pre- and post-ITGent administration. After ITGent administration, 4 patients did not show any MRI modification, 3 patients showed a worsening of EH in one site, and 1 patient showed a worsening in two sites. No subjects presented reduction of EH. No evidence of reduced EH following ITGent treatment has been shown in the present imaging investigation.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1537-4505
1537-4505
DOI:10.1097/MAO.0b013e318248ee1f